Objective To investigate the antioxidant effect of matrine and its clinical effect in the treatment of rats with nonalcoholic steatohepatitis( NASH). Methods A total of 30 rats were randomly divided into three groups: control group,NASH group,and matrine group,with 10 in each. A high- fat diet was used to establish the rat model of NASH,and matrine was given by gavage for treatment at a dose of36 mg·kg- 1·d- 1. The changes in body weight and liver weight were observed in all rats. HE staining was used to observe the histopathological changes of the liver. The serum levels of alanine aminotransferase( ALT) and aspartate aminotransferase( AST) and the content of reduced glutathione( GSH),superoxide dismutase( SOD),and malondialdehyde( MDA) in liver tissue were measured. A one- way analysis of variance was used for the comparison between multiple groups,and the SNK- q test was used for further comparison between any two groups. Results Compared with the NASH group,the matrine group had significant reductions in the serum levels of ALT and AST( ALT:52. 0 ± 3. 0 U / L vs 41. 8 ± 3. 7 U / L,P < 0. 001; AST: 233. 6 ± 9. 4 U / L vs 170. 1 ± 1. 8 U / L,P < 0. 001). The matrine group showed marked improvement in the histopathological changes of the liver compared with the NASH group. Compared with the NASH group,the matrine group had significantly increased content of SOD and GSH in liver tissue( SOD: 17. 7 ± 2. 0 μg / mg vs 27. 0 ± 3. 6 μg / mg,P < 0. 001;GSH: 16. 5 ± 1. 6 U / mg vs 28. 5 ± 2. 1 U / mg,P < 0. 001) and significantly reduced content of MDA( 22. 9 ± 1. 9 nmol / mg vs 17. 8 ± 1. 8nmol / mg,P < 0. 001). Conclusion Matrine has an antioxidant effect and a marked clinical effect in the treatment of rats with NASH.
[1]SCHWENGER KJ,ALLARD JP.Clinical approaches to non-alcoholic fatty liver disease[J].World J Gastroenterol,2014,20(7):1712-1723.
|
[2]ARULANANDAN A,LOOMBA R.Non-invasive testing for NASH and NASH with advanced fibrosis:Are we there yet?[J].Curr Hepatol Rep,2015,14(2):109-118.
|
[3]MA JM,WANG JQ.Treatment of non-alcoholic fatty liver disease from deficiency[J].J Changchun Univ Tradit Chin Med,2014,30(10):850-852.(in Chinese)马菁蔓,王景泉.从虚论治非酒精性脂肪肝[J].长春中医药大学学报,2014,30(10):850-852.
|
[4]LE TA,LOOMBA R.Management of non-alcoholic fatty liver disease and steatohepatitis[J].J Clin Exp Hepatol,2012,2(2):156-173.
|
[5]DAY CP,JAMES OF.Steatohepatitis:a tale of two“hits”?[J].Gastroenterology,1998,114(4):842-845.
|
[6] The Chinese National Workshop on Fatty Liver and Alcoholic Liver disease for the Chinese Liver Disease Association.Guidelines for management of nonalcoholic fatty liver disease:an updated and revised edition[J].J Clin Hepatol,2010,26(2):120-124.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南(2010年修订版)[J].临床肝胆病杂志,2010,26(2):120-124.
|
[7]CALZADILLA BL,ADAMS LA.The natural course of nonalcoholic fatty liver disease[J].Int J Mol Sci,2016,17(5):774.
|
[8]XIONG J,WANG J,HUANG J,et al.Non-alcoholic steatohepatitis-related liver cirrhosis is increasing in China:a tenyear retrospective study[J].Clinics(Sao Paulo),2015,70(8):563-568.
|
[9]GONG S,SUN JM,TIAN LL,et al.Research progress of the anti-tumor effect of alkaloids of natural medicine[J].Jilin J Tradit Chin Med,2014,34(9):927-931.(in Chinese)宫爽,孙佳明,田淋淋,等.天然药物中生物碱类成分抗肿瘤活性[J].吉林中医药,2014,34(9):927-931.
|
[10]SHEN H,NIE HM,CHEN YY,et al.Status of treatments of traditional on chronic hepatitis B[J].J Changchun Univ Chin Med,2015,31(4):873-876.(in Chinese)申弘,聂红明,陈逸云,等.慢性乙型肝炎的中医药治疗[J].长春中医药大学学报,2015,31(4):873-876.
|
1. | 丁辉,苏雪梅,张蓉. 子宫内膜异位症患者血清GP73和SMAD2表达水平及临床价值研究. 现代检验医学杂志. 2025(01): 122-126+131 . ![]() | |
2. | 王慧敏,谭炳芹,王万鹏,吴梦雪. 慢性乙型肝炎病毒感染相关肝病患者血清高尔基体蛋白73水平变化分析. 山东医药. 2025(01): 100-103+108 . ![]() | |
3. | 张璨,张欢欢,高飞,任佩佩,罗明阳,闫冬,王馨,王莹莹,曾艳丽. 血清高尔基体蛋白73联合肝脏硬度评估慢性乙型肝炎病毒感染患者肝纤维化进展的价值. 中华实用诊断与治疗杂志. 2024(10): 1013-1018 . ![]() | |
4. | 李述美,刘冰,刘仁伟,杨洁. GP73、IL-2R、miR-21预测慢性乙肝患者显著肝纤维化的临床价值. 重庆医学. 2024(23): 3575-3580 . ![]() | |
5. | 安薪宇,乔杰,胡灵溪,王荣琦,南月敏. GP73对慢性肝病患者肝纤维化诊断价值的研究. 中华内科杂志. 2023(01): 49-53 . ![]() | |
6. | 张航,刘近春. 血清高尔基体蛋白73在非酒精性脂肪性肝病中的作用. 临床肝胆病杂志. 2023(03): 657-662 . ![]() | |
7. | 马杨青,范海纳,孙鑫,刘成海. 高尔基体蛋白73(GP73)对慢性肝病的诊断价值. 临床肝胆病杂志. 2023(08): 1999-2004 . ![]() | |
8. | 张欢,雷学忠. 新型血清标志物高尔基体蛋白73在慢性乙型肝炎临床诊治中的研究进展. 华西医学. 2023(08): 1243-1246 . ![]() | |
9. | 陈腾千,姜丽华,张生君,蒋义贵,罗佳,胡永敏,尤丽财. 高尔基体蛋白73在非酒精性脂肪性肝病中的应用价值. 黑龙江医学. 2023(17): 2053-2055+2059 . ![]() | |
10. | 李雨蓉,姚明解,王杰. 序贯无创检测提高肝纤维化筛查效率. 肝脏. 2023(10): 1146-1149 . ![]() | |
11. | 刘燕娜,姚明解,郑素军,陈香梅,刘向祎,胡鹏,欧启水,窦晓光,陈红松,段钟平,侯金林,南月敏,高志良,徐小元,庄辉,鲁凤民. 血清高尔基体蛋白73在慢性肝病患者中的临床应用. 中华肝脏病杂志. 2022(01): 4-8 . ![]() | |
12. | 裴倩云,孙颖. 血清免疫球蛋白检验在肝衰竭患者的诊断价值. 系统医学. 2022(15): 103-105+118 . ![]() | |
13. | 王鹏飞,刘树红,钱相君,翟相威,文夏杰,姚明解,赵景民,鲁凤民. 血清高尔基体蛋白73对丙型肝炎肝硬化的诊断价值研究. 中华肝脏病杂志. 2022(08): 879-884 . ![]() | |
14. | 郑伟明,罗翠转,卢金英,骆晓豪,刘浩,梁栋伟. 血过氧化物酶增殖体激活受体γ与慢性乙型肝炎患者炎症的相关性. 中国肝脏病杂志(电子版). 2022(04): 42-47 . ![]() | |
15. | 庄云英,张海燕,曾清芳. 慢性乙型肝炎肝纤维化的无创诊断研究进展. 肝脏. 2021(01): 84-87 . ![]() | |
16. | 刘燕娜,姚明解,鲁凤民. 慢性肝病患者中血清高尔基体蛋白73的临床应用. 肝脏. 2021(02): 103-106 . ![]() | |
17. | Application of serum Golgi protein-73 in the management of chronic liver disease. 中华医学杂志英文版. 2021(07): 777-779 . ![]() | |
18. | 罗双艳,何颖. 慢性乙肝患者肝脏炎症及纤维化的影响因素及其与血清高尔基体蛋白73的相关性. 医学信息. 2021(15): 5-8 . ![]() | |
19. | 高伟,高虹,尹春梅,杨森林,范晓红,刘春亮,李雪卿,贾妮娜. 血清GP73与p62测定对HBV相关慢加急性肝衰竭患者短期预后的预测价值比较. 中华肝脏病杂志. 2021(09): 855-860 . ![]() | |
20. | 王一奇,苑喜微,李冬冬,汤玉会,薛宁宁,崔璐瑶,刘领弟,南月敏. 血浆高尔基体蛋白73及相关模型诊断非酒精性脂肪性肝病的研究. 中华肝脏病杂志. 2021(12): 1170-1176 . ![]() | |
21. | 张春林. 患儿脓毒症继发肝损伤的危险因素及血清高尔基体跨膜糖蛋白73、微小RNA-122a水平变化. 中国临床医生杂志. 2020(02): 236-238 . ![]() | |
22. | 刘沁雨,常越,张青,丁玉平,李海. 高尔基体蛋白73对抗病毒治疗慢性乙型肝炎患者代偿期肝硬化的诊断价值. 解放军医药杂志. 2020(03): 86-91 . ![]() | |
23. | 翟相威,刘树红,姚明解,钱相君,文夏杰,许强,赵景民,鲁凤民. 基于血清高尔基体蛋白73的代偿期乙型肝炎肝硬化无创诊断模型的建立及初步应用. 中华肝脏病杂志. 2020(01): 47-52 . ![]() | |
24. | 范旭,单珊,刘立伟,贾继东. 血清高尔基糖蛋白73优于APRI、FIB-4对慢性HBV感染患者显著纤维化的诊断. 现代消化及介入诊疗. 2020(04): 529-532 . ![]() | |
25. | 范旭,单珊,刘立伟,贾继东. 血清高尔基体跨膜糖73蛋白及其他生物标志物联合检测在AFP阴性小肝癌诊断中的意义. 现代消化及介入诊疗. 2020(04): 435-439+443 . ![]() | |
26. | 刘沁雨,常越,张文,张青,卢诚震,李海. GP73预测慢性乙型肝炎患者肝硬化进展研究. 武警医学. 2020(04): 317-323 . ![]() | |
27. | 马玲玉,甄一宁,罗云萍,段昭君. gp73在小鼠肝纤维化肝组织中的表达及机制. 基础医学与临床. 2020(06): 771-776 . ![]() | |
28. | 刘沁雨,常越,张青,丁玉平,李海. 血清GP73与PYGO2对已长期抗病毒治疗慢性乙型肝炎肝硬化的诊断价值. 山东医药. 2020(29): 64-66 . ![]() | |
29. | 李佳娜,郑瑞琦,李娜,胡玉琳. 高尔基体蛋白73的生物学特征及在肝纤维化和肝硬化中的诊断价值. 临床肝胆病杂志. 2019(06): 1361-1364 . ![]() | |
30. | 王春艳,纪冬,马丽君,陈松海,王晶晶,邵清,陈国凤,韩萍. 慢性乙型肝炎患者血清高尔基体蛋白73及其与肝脏炎症及纤维化的相关性. 解放军医学杂志. 2019(06): 503-507 . ![]() | |
31. | 宋莹,李世朋,焦伟伟. 血清HMGB1、TGFβ1及GP73检测对脓毒症并发肝损伤预后的评估价值. 分子诊断与治疗杂志. 2019(06): 457-461 . ![]() |